Search

The problem of food safety of the country is the main task of grain-growing economic entities. Spring wheat occupies an important place in achieving this goal due to the quality of the products obtained. As a result of the pathological process, diseases of fungal etiology lead to a decrease in the yield of the crop, and also, due to biochemical changes in the affected plants, to a decline in its quality. Against the background of compliance with agrotechnical requirements for the cultivation of spring wheat, the biologically justified use of fungicides (when the development of one or a complex of diseases reaches a threshold level) in order to protect the leaves from diseases (powdery mildew, a complex of leaf spots, etc.) during the growing season is a highly effective technique. Analysis of the results of long-term research (2010–2021) on the study of the biological effectiveness of 27 fungicides consisting of various combinations of active substances showed that, in general, single-component preparations provided a limitation of the severity of leaf spots by an average of 44,1–55,3 %, powdery mildew – by 43,0–85,1 %, two-component – by 61,9–83,4 and 60,0–78,3 %, three-component – by 68,7–88,9 and 70,2–90,9 %, respectively. Timely fungicidal treatment will save up to 30,4 % of the crop (a combination of azole and strobilurin).

Carcinogenesis research uncovers new pathogenesis links as vulnerable targets of effective antitumour therapies. Among the key mediators of immune response, cell proliferation, cell apoptosis and inflammation is transcription factor NF-κB. Misregulation of an NF-κB-dependent pathway is found in solid and haematopoietic tumour cells. One of the best known NF-κB functions is expression regulation of genes involved in the apoptosis inhibition or activation and survival in both intact and malignant cells. The NF-κB-mediated pathways’ involvement in carcinogenesis, angiogenesis and tumour resistance to chemo- and radiotherapies makes this factor a promising target for drug anti-cancer interventions. This review summarises evidence on the antitumour and anti-inflammatory activity of a high-potent and specific low molecular-weight NF-κB inhibitor, dehydroxymethylhepoxyquinomycin (DHMEQ), as a candidate therapeutic agent in treatment for variant malignancies.